← Back to Search
Chemoprevention Of Colorectal Cancer.
Bryson W. Katona, J. Weiss
Published 2019 · Medicine
Download PDFAnalyze on Scholarcy
Although colorectal cancer (CRC) screening has reduced the incidence and mortality from CRC, chemoprevention strategies have potential to further reduce CRC incidence and mortality. Chemoprevention agents might be used for average-risk as well as high-risk groups, and to prevent colorectal cancer recurrence after therapy. CRC chemoprevention agents that have been studied include aspirin, non-aspirin non-steroidal anti-inflammatory drugs, statins, agents that target metabolic pathways, and vitamins and minerals. We review the prospect of chemoprevention of CRC, results from preclinical and human studies, challenges, and future directions.
This paper references
Aspirin and the risk of colorectal cancer in women.
E. Giovannucci (1995)
Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial
N. Cook (2013)
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies
E. Flossmann (2007)
A prospective cohort study of intake of calcium, vitamin D, and other micronutrients in relation to incidence of rectal cancer among postmenopausal women.
W. Zheng (1998)
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.
A. M. Algra (2012)
Celecoxib for the prevention of colorectal adenomatous polyps.
N. Arber (2006)
Approaches to prevention of epithelial cancer during the preneoplastic period.
M. Sporn (1976)
Colorectal polyp prevention by daily aspirin use is abrogated among active smokers
David A. Drew (2015)
Aspirin: A Historical and Contemporary Therapeutic Overview
V. Fuster (2011)
Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: A systematic review and meta-analysis.
Tanja Tomić (2019)
No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial
Audrey H Calderwood (2019)
Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells.
Xufeng Qi (2010)
Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population.
T. Levin (2018)
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence.
E. Jacobs (2007)
The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers.
G. Omenn (1994)
Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system.
D. Corpet (2003)
The Use of Metformin and Colorectal Cancer Incidence in Patients with Type II Diabetes Mellitus
Brielan B. Smiechowski (2013)
Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinase
K. Hosono (2010)
Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies.
Yanlei Ma (2011)
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
A. Waechtershaeuser (2001)
The Long-Term Use of Statins Is Associated with a Decreased Incidence of Adenomatous Colon Polyps
A. Siddiqui (2009)
Molecular Nature of the Vitamin D Receptor and its Role in Regulation of Gene Expression
P. Jurutka (2004)
Intakes of vitamins A, C, and E and use of multiple vitamin supplements and risk of colon cancer: a pooled analysis of prospective cohort studies
Y. Park (2010)
Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012.
Q. Gu (2014)
Statins and the risk of colorectal cancer.
J. Poynter (2005)
Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity
M. Ebrahimi (2009)
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
C. Currie (2009)
Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study
C. Lin (2015)
Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
M. Cruz-Correa (2002)
Metformin use and the risk of colorectal adenoma: A systematic review and meta‐analysis
Y. Jung (2017)
Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta‐analysis
D. Papaioannou (2011)
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
J. Baron (2006)
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
X. Liao (2012)
Molecular targets of curcumin.
J. Lin (2007)
Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force
Jessica Chubak (2016)
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours
C. Coyle (2016)
Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan.
C. Tseng (2012)
Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials
Tingting Qin (2015)
Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study
Til Sturmer (1998)
Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women.
M. J. Reeves (1996)
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
P. Rothwell (2010)
Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials.
S. Bonovas (2006)
Effect of eicosapentaenoic acid on the proliferation and incidence of apoptosis in the colorectal cell line HT29
Rosemary G. Clarke (1999)
A randomized trial of aspirin to prevent colorectal adenomas.
J. Baron (2003)
New Users of Metformin Are at Low Risk of Incident Cancer
G. Libby (2009)
Effect of folic acid supplementation on the progression of colorectal aberrant crypt foci.
Gillian Lindzon (2009)
Dietary Calcium and Vitamin D Intake and Risk of Colorectal Cancer: A Prospective Cohort Study in Women
P. Terry (2002)
Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive services Task Force recommendation statement.
V. Moyer (2014)
Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals
E. Giovannucci (1994)
Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention
S. Padayatty (2003)
Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies
P. Elwood (2016)
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
K. Bibbins-Domingo (2016)
Dietary intake of folic acid and colorectal cancer risk in a cohort of women
P. Terry (2002)
Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.
S. Winawer (1993)
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial
R. Bulbulia (2011)
Inhibition of Intestinal Polyp Formation by Pitavastatin, a HMG-CoA Reductase Inhibitor
Naoya Teraoka (2011)
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
J. McNeil (2018)
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
J. Burn (2011)
Ornithine decarboxylase activity in the rat and human colon.
J. Rozhin (1984)
Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
Driss Ait Ouakrim (2015)
Celecoxib for the prevention of sporadic colorectal adenomas.
M. Bertagnolli (2006)
Aberrant Crypt Foci of the Colon as Precursors of Adenoma and Cancer
T. Takayama (1998)
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
S. Grivennikov (2012)
IL-23 promotes tumour incidence and growth
John L. Langowski (2006)
Primary chemoprevention of familial adenomatous polyposis with sulindac.
F. Giardiello (2002)
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
S. Solomon (2005)
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals
Meei-Shyuan Lee (2010)
Folate supplementation and adenomatous colonic polyps
G. Paspatis (1994)
Vitamin A and immunity to viral, bacterial and protozoan infections.
R. Semba (1999)
Reliability and accuracy of the endoscopic appearance in the identification of aberrant crypt foci.
A. Gupta (2009)
Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk
S. Friis (2015)
Randomized Double-Blind Trial of Sulindac and Etodolac to Eradicate Aberrant Crypt Foci and to Prevent Sporadic Colorectal Polyps
T. Takayama (2011)
Statins and colorectal cancer.
P. Lochhead (2013)
Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer.
W. Elsheikh (2014)
Reported Use of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Was Not Associated with Reduced Recurrence of Colorectal Adenomas
J. Wei (2005)
A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Tetsuro Higuchi (2003)
Current Status of Folic Acid Supplementation on Colorectal Cancer Prevention
Y. Kim (2016)
Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
S. Dehmer (2016)
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
P. Gazzerro (2012)
Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH
J. Wang (2018)
Folate intake and colorectal cancer risk: A meta‐analytical approach
M. A. Sanjoaquin (2005)
Dietary n-3 PUFA increases the apoptotic response to 1,2-dimethylhydrazine, reduces mitosis and suppresses the induction of carcinogenesis in the rat colon.
P. Latham (1999)
Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer
A. Cockbain (2011)
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
R. Sandler (2003)
Routine Vitamin Supplementation To Prevent Cancer and Cardiovascular Disease: Recommendations and Rationale
U. P. S. T. Force (2003)
Coxibs and Other Nonsteroidal Anti-Inflammatory Drugs in Animal Models of Cancer Chemoprevention
S. Fischer (2011)
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.
R. Benamouzig (2003)
Long-Chain Omega-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer
E. Kantor (2014)
Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study
Majken Cardel (2014)
Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer
L. Emilsson (2018)
Metformin suppresses intestinal polyp growth in ApcMin/+ mice
A. Tomimoto (2008)
Statin use and cancer risk: a comprehensive review
D. Boudreau (2010)
Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH‐naproxen (AVT‐219) a dual NO‐ and H2S‐releasing hybrid
Mitali Chattopadhyay (2016)
Statins and cancer: A systematic review and meta-analysis.
J. Kuoppala (2008)
Calcium intake and risk of colon cancer in women and men.
K. Wu (2002)
A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis
J. Burn (2011)
Folic acid intake and folate status and colorectal cancer risk: A systematic review and meta-analysis.
S. Moazzen (2018)
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
G. Steinbach (2000)
Low-dose aspirin and incidence of colorectal tumors in a randomized trial.
P. Gann (1993)
Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis
S. Singh (2013)
Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
J. Emberson (2012)
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
J. Manson (2019)
Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas.
J. Baron (1998)
Long-term colorectal-cancer incidence and mortality after lower endoscopy.
R. Nishihara (2013)
Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial
R. Benamouzig (2011)
Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer.
Carlien Leyssens (2013)
The role of vitamin D in reducing cancer risk and progression
D. Feldman (2014)
Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings.
R. P. Bird (1987)
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
B. Cole (2007)
Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial
F. Meyskens (2008)
Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial
N. Samadder (2018)
Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review.
L. Sharp (2004)
Systematic review with meta‐analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention
L. Emilsson (2017)
Antioxidant and prooxidant properties of carotenoids.
A. Young (2001)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
R. Bresalier (2005)
Proceedings: Prostaglandins in human colonic carcinoma.
Colorectal Cancer Prevention
E. Hawk (2005)
Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force
A. Rostom (2007)
Role of AMP-activated protein kinase in mechanism of metformin action.
G. Zhou (2001)
Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial
N. Cook (2005)
Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial
C. Burke (2016)
Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial
M. Bertagnolli (2010)
Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group.
J. Baron (1999)
Prostaglandins and cancer: an update.
B. Jaffe (1974)
Genetic Variation in 3-Hydroxy-3-Methylglutaryl CoA Reductase Modifies the Chemopreventive Activity of Statins for Colorectal Cancer
S. Lipkin (2010)
A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus
M. Bradley (2018)
Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis.
P. Craven (1992)
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
T. Higurashi (2016)
Metformin for primary colorectal cancer prevention in patients with diabetes: A case‐control study in a US population
Amikar Sehdev (2015)
Vitamin A and cancer.
R. Niles (2000)
Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States)
M. McCullough (2004)
Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis
N. J. West (2010)
Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer.
Yin Cao (2016)
Protective role of vitamin E in biological systems.
L. Packer (1991)
Long-term mortality after screening for colorectal cancer.
A. Shaukat (2013)
Protection From Colorectal Cancer After Colonoscopy
H. Brenner (2011)
Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention
Peter M. Lance (2008)
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
F. Giardiello (1993)
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
M. Swamy (2006)
Vitamin D and colon carcinogenesis.
D. Harris (2004)
Use of Metformin Is Not Associated with a Decreased Risk of Colorectal Cancer: A Case–Control Analysis
M. Bodmer (2011)
Folate and carcinogenesis: an integrated scheme.
S. W. Choi (2000)
Inhibition of dietary fat-promoted colon carcinogenesis in rats by supplemental calcium or vitamin D3.
B. Pence (1988)
Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial
E. Barry (2017)
Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin.
C. Barnes (1998)
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
J. Burn (2008)
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
N. J. Samadder (2016)
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
B. Cole (2009)
Metastatic colorectal cancer: current state and future directions.
M. Fakih (2015)
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats.
B. Reddy (1993)
Meta‐analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma
G. Bjelakovic (2006)
Effect of Aspirin on All‐Cause Mortality in the Healthy Elderly
J. McNeil (2018)
Aspirin and colorectal cancer: the promise of precision chemoprevention
David A. Drew (2016)
Statins and risk of cancer: A systematic review and metaanalysis
D. Browning (2007)
Statins and cancer risk: a meta-analysis.
K. M. Dale (2006)
Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
R. Harris (2007)
Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis
Feifei Liu (2017)
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
I. Ben-Sahra (2008)
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial
David A. Drew (2017)
Nonsteroidal Anti-inflammatory Drug Use and Risk of Adenomatous and Hyperplastic Polyps
H. Murff (2011)
Colorectal Cancer Risk Following Adenoma Removal: A Large Prospective Population-Based Cohort Study
H. Coleman (2015)
Meta‐analysis: folic acid in the chemoprevention of colorectal adenomas and colorectal cancer
C. Carroll (2010)
Use of biguanides and the risk of colorectal cancer: a register-based cohort study.
L. M. Knapen (2013)
Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study
C. Doubeni (2018)
The Effect of α-Tocopherol and β-Carotene Supplementation on Colorectal Adenomas in Middle-Aged Male Smokers
N. Malila (1999)
The statins as anticancer agents.
K. Chan (2003)
Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial
S. Crockett (2018)
Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.
H. Nan (2015)
Diabetes mellitus and risk of colorectal cancer: a meta-analysis.
S. Larsson (2005)
Cardiovascular Safety and Bleeding Risk Associated with Nonsteroidal Anti-Inflammatory Medications in Patients with Cardiovascular Disease
S. Ross (2017)
An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis
P. Lynch (2015)
Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.
G. Kune (1988)
The Molecular Pathogenesis of Colorectal Cancer and Its Potential Application to Colorectal Cancer Screening
W. Grady (2014)
Profound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal Tumorigenesis
M. Paul-Clark (2016)
Aspirin dose and duration of use and risk of colorectal cancer in men.
A. Chan (2008)
Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis.
M. Cruz-Correa (2018)
The Adenomatous Polyposis Coli Tumor Suppressor Gene Regulates Expression of Cyclooxygenase-2 by a Mechanism That Involves Retinoic Acid*
Annie L Eisinger (2006)
Statin Use and Colorectal Cancer Risk According to Molecular Subtypes in Two Large Prospective Cohort Studies
J. Lee (2011)
The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial
H. Ishikawa (2014)
The association between statins and cancer incidence in a veterans population.
W. Farwell (2008)
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.
O. Heinonen (1994)
Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer.
A. Rodríguez-Miguel (2018)
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
J. Gaziano (2018)
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
A. Chan (2007)
Long-term follow-up of the West of Scotland Coronary Prevention Study.
I. Ford (2007)
Folate status and adenomatous colonic polyps
G. Paspatis (1995)
Statins and cancer: a meta-analysis of case–control studies
M. Taylor (2008)
Combination of Atorvastatin with Sulindac or Naproxen Profoundly Inhibits Colonic Adenocarcinomas by Suppressing the p65/β-Catenin/Cyclin D1 Signaling Pathway in Rats
N. Suh (2011)
Multivitamin Use, Folate, and Colon Cancer in Women in the Nurses' Health Study
E. Giovannucci (1998)
Immunocytochemical Localization of the Extracellular Calcium-Sensing Receptor in Normal and Malignant Human Large Intestinal Mucosa
Y. Sheinin (2000)
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial
M. Hull (2018)
Selenoproteins and cancer prevention.
C. Davis (2012)
Aberrant crypts: potential preneoplastic lesions in the murine colon.
E. McLellan (1988)
Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial.
R. Jaszewski (2008)
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
K. Saku (2011)
The utility of Aspirin in dukes C and high risk dukes B colorectal cancer - The ASCOLT study: study protocol for a randomized controlled trial
R. Ali (2011)
A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma
A. Chan (2004)
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK
B. Kowall (2015)
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives
A. Mohammed (2018)
IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma
F. Lan (2011)
Role of calcium in colon cancer prevention: experimental and clinical studies.
B. Pence (1993)
The Akt-mTOR tango and its relevance to cancer.
N. Hay (2005)
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
P. Rothwell (2012)
Aspirin and folic acid for the prevention of recurrent colorectal adenomas.
R. Logan (2008)
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.
R. Coffey (1997)
Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial
M. Bertagnolli (2009)
A Way Forward for Cancer Chemoprevention: Think Local
Luai Al Rabadi (2016)
A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas.
J. Baron (2015)
A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma.
K. Wu (2009)
Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes
Zhi-Jiang Zhang (2011)
Calcium plus vitamin D supplementation and the risk of colorectal cancer.
J. Wactawski-Wende (2006)
Vitamin E: mechanisms of action as tumor cell growth inhibitors.
K. Kline (2001)
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.
R. Schoen (2012)
Chemoprevention of colorectal neoplasia: the potential for personalized medicine.
N. Arber (2008)
The management of prenatally diagnosed choledochal cysts.
T. MacKenzie (2001)
This paper is referenced by
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives
A. Mohammed (2018)
An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer
Jeffrey A Rappaport (2020)
Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help?
W. Maguire (2020)
Aspirin rescues Wnt-driven stem-like phenotype in human intestinal organoids and increases the Wnt antagonist Dickkopf-1.
Karen Dunbar (2020)